IMAGET

IMAGET

Description

The discovery of imatinib, a signal transduction inhibitor, towards the end of the last century revolutionized the treatment of Chronic Myelogenous Leukemia (CML). Excellent haematological response as well as cytogenetic response made imatinib the standard of care in CML. It is and belongs to the category of EGFR-tyrosine kinase inhibitors.

Indications:

• Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)
• Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy
• Ph+ Acute Lymphoblastic Leukemia (ALL)
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)
• Aggressive Systemic Mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown
• Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and also if fusion kinase negative or unknown
• Dermatofibrosarcoma Protuberans (DFSP)
• Kit+ Gastrointestinal Stromal Tumors (GIST)
• Adjuvant Treatment of GIST

Enquire Now